David A. Ricks is Chairman, President & Chief Executive Officer at Eli Lilly & Co. since 2017. He is Chairman & Chief Executive Officer at Eli Lilly & Co. Ltd. and Eli Lilly Italia SpA. He serves as Chairman-Governors Board at James Whitcomb Riley Children's Foundation. He is an Independent Director at Adobe, Inc. since 2018. He is Director at Pharmaceutical Research & Manufacturers of America since 2022. He is Director at The Central Indiana Corporate Partnership. He is a Member of The Business Roundtable and The Business Council. Former roles include Director at European Federation of Pharmaceutical Industries & Assns, Director at Elanco Animal Health, Inc. from 2018 to 2019, Principal at HP, Inc., Principal at International Business Machines Corp., President at International Federation of Pharmaceutical Manufacturers, President at Lilly USA LLC from 2009 to 2012, President & General Manager at Lilly Industries Shanghai Ltd. in 2009, and General Manager at Eli Lilly Canada, Inc. from 2005 to 2008. Education includes an MBA from Indiana University in 1996 and an undergraduate degree from Purdue University in 1990.
Nathaniel R. Miles
Nathaniel R. Miles is currently the Chairman of Urban League of Metropolitan Seattle. He also holds the position of Director at Hightowers Petroleum Co., University of Washington Foundation, Alliance for Education, Association of Washington Business, Eli Lilly & Co., and National Association for the Advancement of Colored People. In the past, Mr. Miles has worked as a Director at Medical Teams International, Centerstone of Indiana, Inc., Washington State Convention & Trade Center, Boys & Girls Clubs of King County, Overlake Hospital Foundation, and Puget Sound Regional Council. Mr. Miles completed his undergraduate degree at the University of Washington.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
David A. Ricks
David A. Ricks is Chairman, President & Chief Executive Officer at Eli Lilly & Co. since 2017. He is Chairman & Chief Executive Officer at Eli Lilly & Co. Ltd. and Eli Lilly Italia SpA. He serves as Chairman-Governors Board at James Whitcomb Riley Children's Foundation. He is an Independent Director at Adobe, Inc. since 2018. He is Director at Pharmaceutical Research & Manufacturers of America since 2022. He is Director at The Central Indiana Corporate Partnership. He is a Member of The Business Roundtable and The Business Council. Former roles include Director at European Federation of Pharmaceutical Industries & Assns, Director at Elanco Animal Health, Inc. from 2018 to 2019, Principal at HP, Inc., Principal at International Business Machines Corp., President at International Federation of Pharmaceutical Manufacturers, President at Lilly USA LLC from 2009 to 2012, President & General Manager at Lilly Industries Shanghai Ltd. in 2009, and General Manager at Eli Lilly Canada, Inc. from 2005 to 2008. Education includes an MBA from Indiana University in 1996 and an undergraduate degree from Purdue University in 1990.
Donald A. Zakrowski
Donald A. Zakrowski is currently Chief Accounting Officer & Senior VP-Finance at Eli Lilly & Co., a position held since 2012. Formerly, Mr. Zakrowski was a Senior Manager at PricewaterhouseCoopers LLP.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Robert J. Heine
Robert J. Heine has a current job as the Vice President-Medical Affairs at Eli Lilly & Co.
Daniel M. Skovronsky
Daniel M. Skovronsky was the founder of Avid Radiopharmaceuticals, Inc., founded in 2004, where the title held was Chief Executive Officer. Current jobs include Independent Director at Myriad Genetics, Inc. since 2020; Chief Scientific & Product Officer at Eli Lilly & Co. starting in 2024; Member at the University of Pennsylvania; Member-Governance Board at Indianapolis Museum of Art, Inc.; and President, Chief Scientific Officer & Senior Vice President at Lilly Research Laboratories since 2018. Education history includes a doctorate from the University of Pennsylvania in 2000 and a doctorate from Perelman School of Medicine in 2001.
Lucas E. Montarce
Mr. Lucas E. Montarce is a Chief Financial Officer, Group VP & Controller at Lilly Research Laboratories and a Chief Financial Officer & Executive Vice President at Eli Lilly & Co. He is on the Board of Directors at Christel House International, Inc. Mr. Montarce was previously employed as a Vice President by Elanco Animal Health, Inc. He received his undergraduate degree from The Catholic University of America and an MBA from Universidad del CEMA.
Robert Conley
Robert Conley has worked at Eli Lilly & Co. since 2017 as a Development Leader-Neuroscience.
Anat Hakim
Ms. Anat Hakim is a Secretary, Executive VP & General Counsel at Eli Lilly & Co. Ms. Hakim was previously employed as a Secretary, Executive VP & General Counsel by WCG Health Management, Inc., a Divisional VP & Associate General Counsel by Abbott Laboratories, an Equity Partner by Foley & Lardner LLP, and an Associate by Latham & Watkins LLP. She received her undergraduate degree from the University of Wisconsin and a graduate degree from Harvard Law School.
Patrik Jonsson
Patrik Jonsson currently works at Eli Lilly & Co., as Executive VP & President-Lilly International from 2025. Mr. Jonsson also formerly worked at The American Chamber of Commerce in Japan, as Director, Eli Lilly Italia SpA, as President & General Manager, and Lilly USA LLC, as President. Mr. Jonsson received his undergraduate degree from Lund University School of Economics & Management.
Ilya Yuffa
Ilya Yuffa currently works at European Federation of Pharmaceutical Industries & Assns, as Director, The U.S.-Japan Business Council, Inc., as Director, Eli Lilly & Co., as Executive VP- Global Customer Capabilities from 2025, and Lilly USA LLC, as President from 2025. Mr. Yuffa also formerly worked at Farmindustria, as Director. Mr. Yuffa received his undergraduate degree in 1996 from Tulane University (Louisiana) and Masters Business Admin degree in 2002 from London Business School.
Edgardo Hernandez
Edgardo Hernandez is currently working as the President-Manufacturing Operations & Senior VP at Eli Lilly & Co. He started this position in 2021. Prior to his current role, he obtained a graduate degree from North Carolina State University and an undergraduate degree from the University of Puerto Rico.
Diogo Rau
Diogo Rau is the founder of GiftGateway, founded in 1999. Mr. Rau is currently Chief Information & Digital Officer, Executive VP at Eli Lilly & Co. since 2021. Former jobs include Senior Director-Information Systems & Technology at Apple, Inc. from 2011 to 2021, and Partner at McKinsey & Co., Inc. from 2003 to 2011. Education includes undergraduate and graduate degrees from Stanford University.
Christian Nguyen
Christian Nguyen has worked as a Director at the National Pharmaceutical Council since 2021 and holds the position of VP-Global Patient Outcomes & Real World Evidence at Eli Lilly & Co.
Andy Vicari
Andy Vicari currently works at Eli Lilly & Co., as Senior Director & US Brand Leader-Insulins and American Diabetes Association, as Member-Indiana Community Leadership Board.
Kim Macko
Eli Lilly & Co.'s Head-Global Brand Development is currently held by Kim Macko.
Eric Dozier
Eric Dozier currently holds the position of Director at Christian Theological Seminary, Inc., Director at Center for Leadership Development, Inc., Director at Indianapolis Airport Authority (Indiana), and Chief People Officer & Executive Vice President at Eli Lilly & Co., a role held since 1998. Mr. Dozier's education includes an MBA from Indiana University and an undergraduate degree from The Ohio State University.
Laura A. Lane
Laura A. Lane was the founder of Virion Biotherapeutics Ltd. which was founded in 2015, where she held the title of Chief Operating Officer & Director from 2015 to 2018. Currently, she is a Vice President at Eli Lilly & Co. since 2022. Previously, she worked as a Principal at Advent Venture Partners LLP from 2019 to 2022. Ms. Lane received her undergraduate and doctorate degrees from the University of Cambridge.
Ruth Gimeno
Ruth Gimeno has held positions at BioCrossroads as a Board of Director and at Eli Lilly & Co. as Vice President. Both roles are current.
Mark Genovese
Mark Genovese is currently the Senior Vice President-Immunology Development at Eli Lilly & Co. He previously worked as the Director at Kyverna Therapeutics, Inc. and as the Clinical Chief-Immunology & Rheumatology at Stanford University. From 2020 to 2023, he served as the Senior Vice President-Inflammation Development at Gilead Sciences, Inc. Dr. Genovese completed his undergraduate degree at the University of Notre Dame and obtained his doctorate from The Johns Hopkins University School of Medicine.
David Hyman
David Hyman has worked as a Chief Medical Officer at Eli Lilly & Co. since 2023 and at Loxo Oncology, Inc. since 2020.
Jennifer Oleksiw
Jennifer Oleksiw currently works at Eli Lilly & Co., as Global Chief Customer Officer & Vice President from 2023.
Joe Fletcher
Jacob S. van Naarden
Mr. Jacob S. van Naarden is a President-Lilly Oncology & Executive VP at Eli Lilly & Co. and a Chief Executive Officer at Loxo Oncology, Inc. He is on the Board of Directors at Delfi Diagnostics, Inc. Mr. van Naarden was previously employed as an Analyst by HealthCor Management LP, an Associate by Aisling Capital LLC, and an Analyst by Goldman Sachs & Co. He received his undergraduate degree from Princeton University.
Melissa Seymour
Melissa Seymour is currently Chairman at Parenteral Drug Association since 2026 and Executive Vice President-Global Quality at Eli Lilly & Co. since 2024. Formerly, Ms. Seymour was Chief Quality Officer at Bristol Myers Squibb Co. Education includes an MBA from Duke University and an undergraduate degree from North Carolina State University.
Thomas Fuchs
Thomas Fuchs is currently Director at GeneDx Holdings Corp. since 2025. Dr. Fuchs is also Chief Artificial Intelligence Officer & Senior VP at Eli Lilly & Co. since 2024. Dr. Fuchs holds a doctorate from the Swiss Federal Institute of Technology and a graduate degree from Graz University of Technology.
Carole Ho
Carole Ho is currently an Independent Director at Royalty Pharma Plc and Executive VP & President-Lilly Neuroscience at Eli Lilly & Co., both roles starting in 2025. Former roles include Independent Director at Beam Therapeutics, Inc. (2018–2026), Independent Director at NGM Biopharmaceuticals, Inc. (2020–2024), Chief Medical Officer & Head-Development at Denali Therapeutics, Inc. (2015–2025), VP-Non Oncology Early Clinical Development at Genentech, Inc. (2014–2015), Medical Director at Johnson & Johnson (2006–2007), and Chief Resident-Neurology at The General Hospital Corp. Education includes a doctorate from Weill Cornell Medicine and an undergraduate degree from Harvard College.
Michael Czapar
Michael Czapar currently works at ELI Lilly Leasing Ltd., as Director from 2021 and Eli Lilly & Co., as Senior Vice President-Investor Relations from 2024.
提供，免责声明：天汇财经、Factset及其他信息供应商努力确保所提供信息的准确性和可靠性，但对于其正确性或可靠性则不予担保，且对于因不正确或疏漏所造成的任何损失或损坏概不负责(无论是有关民事过失、合同或其他方面)。